Infliximab Biosimilar Reimbursement Benchmark Analysis
Biosimilar reimbursement rates are driving infusion practices toward financial losses.
Jerome Castellano
Section
Biologic Benchmarks
8 stories in Biologic Benchmarks.
Biosimilar Reimbursement Rates vs Reference Biologic Spread
Medicare's reimbursement formula penalizes biosimilars priced below their reference drugs.
Mei-Lin Tsou
Payer Contract Reimbursement Rate Benchmarks for Infusion Centers
Distinguish three benchmark types to avoid missing underpayments in infusion contracts.
Renata Szymborska
Spread Economics for High-Volume Infusion Biologics
Margin on infusion biologics hinges on managing product mix, authorizations, and billing precision.
Renata Szymborska
CMS Quarterly ASP Updates and Margin Volatility
CMS bundled rebate rules and 2028 MFP transitions will reshape infusion practice margins.
Renata Szymborska
WAC-Based Payer Contracts and Spread Erosion Risk
Manufacturer list-price cuts erode reimbursement margins for practices on WAC-based contracts.
Renata Szymborska
ASP Plus Methodology for Infusion Biologic Reimbursement
How sequestration and manufacturer pricing cut infusion practice margins below statutory levels.
Mei-Lin Tsou
Revenue per Infusion Benchmarks for Independent Infusion Groups
Revenue per infusion exposes billing breakdowns that volume metrics mask.
Renata Szymborska